Astellas and Pfizer on Friday jointly announced that FDA has approved a New Drug Application for Xtandi (enzalutamide) for a highly aggressive prostate cancer type (CRPC). The approval reflects the positive clinical data delivered by the drug during the Phase III Prosper trial. Xtandi joined Pfizer’s portfolio after it acquired Medivation in September 2016. Medivation had already signed an agreement with Astellas, under which the Japan-based company maintains marketing rights to to the treatment outside the US. Lifescan has already generated sales of $159m in Q1 2018.